The N1 phenotype exerts antitumor activity via recruitment and activation of CD8+ T-cells whereas the N2 phenotype, induced by TGF-β signaling, promotes tumor progression through secretion of growth factors and immunomodulatory cytokines [25,26,27]. The gene discussed is CD8A; the disease is neoplasm.